Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNASDAQ:EFTRNASDAQ:NTHINASDAQ:SIOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.02$0.02$0.06▼$0.33N/AN/A34,287 shsN/AEFTReFFECTOR Therapeutics$0.00+50.0%$0.00$0.00▼$1.47$1K0.223,226 shs28,106 shsNTHINeonc Technologies$6.40-3.2%$7.13$4.11▼$25.00N/AN/A69,201 shs27,734 shsSIOXSio Gene Therapies$0.48$0.46$0.25▼$0.50N/AN/AN/A40,403 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition+81.82%+177.14%+280.39%-26.79%-46.41%EFTReFFECTOR Therapeutics0.00%0.00%0.00%-66.67%-99.98%NTHINeonc Technologies-4.48%-10.31%+8.01%+660,999,900.00%+660,999,900.00%SIOXSio Gene Therapies0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AEFTReFFECTOR Therapeutics 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/ASIOXSio Gene Therapies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics$3.55M0.00N/AN/A($1.94) per share0.00NTHINeonc Technologies$79.99KN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics-$35.81M-$13.08N/A∞N/AN/AN/AN/A7/28/2025 (Estimated)NTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ASIOXSio Gene Therapies-$71.89MN/A0.00∞N/AN/AN/AN/AN/ALatest SIOX, AEHAW, EFTR, and NTHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NTHINeonc TechnologiesN/A-$2.10N/A-$2.10N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AEFTReFFECTOR Therapeutics57.67%NTHINeonc TechnologiesN/ASIOXSio Gene TherapiesN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AEFTReFFECTOR Therapeutics4.70%NTHINeonc TechnologiesN/ASIOXSio Gene Therapies3.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataNTHINeonc Technologies8N/AN/AN/ASIOXSio Gene Therapies12N/AN/ANo DataSIOX, AEHAW, EFTR, and NTHI HeadlinesRecent News About These CompaniesSio Gene Therapies Stock Price HistoryJune 3, 2025 | investing.comSio Gene Therapies Inc (OTC:SIOX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comOpportunity costs of gene therapies. Where do we go from here?August 26, 2024 | pharmaphorum.comGene TherapyAugust 4, 2024 | ajmc.comLisa Jarvis: Would you get tested for an Alzheimer’s gene?May 13, 2024 | siouxcityjournal.comCommercialization Strategies for Cell and Gene TherapiesMay 11, 2024 | fiercepharma.comCell and Gene Therapy Diversity, Equity and InclusionMay 3, 2024 | bcm.eduWalgreens expands specialty pharmacy and investment in gene therapyMay 1, 2024 | healthcarefinancenews.comGene therapy and the germlineApril 22, 2024 | nature.comGene Therapy for Parkinson's DiseaseMarch 31, 2024 | medscape.comSio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per ShareFebruary 2, 2024 | finance.yahoo.comSio Gene Therapies Inc SIOXNovember 22, 2023 | morningstar.comTwo Promising Gene Therapy Stocks Tackling Eye DiseaseNovember 1, 2023 | thestreet.comGene Therapy News and ResearchOctober 28, 2023 | news-medical.netGene Therapy for Erectile DysfunctionOctober 23, 2023 | medscape.comIn Mice, Gene Therapy Helps Restore Movement After Spinal Cord InjurySeptember 27, 2023 | siouxcityjournal.comRetroviral Vectors for Gene TherapySeptember 18, 2023 | medscape.comSio Gene Therapies (NASDAQ: AXGT)July 19, 2023 | fool.comRoivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 BillionJuly 13, 2023 | finance.yahoo.comGene Therapy in a Patient with Sickle Cell DiseaseJune 20, 2023 | nejm.orgNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSIOX, AEHAW, EFTR, and NTHI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.02 0.00 (0.00%) As of 06/10/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.eFFECTOR Therapeutics NASDAQ:EFTR$0.0003 +0.00 (+50.00%) As of 12:24 PM EasterneFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Neonc Technologies NASDAQ:NTHI$6.40 -0.21 (-3.18%) As of 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.Sio Gene Therapies NASDAQ:SIOXSio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
